Product logins

Find logins to all Clarivate products below.


Psoriasis – Access & Reimbursement – Detailed, Expanded Analysis

Related Market Assessment Reports

Report
Psoriasis – Access & Reimbursement – Access & Reimbursement – Psoriasis (US)
The U.S. psoriasis treatment landscape is rapidly evolving, with newer, more effective therapies increasing competition for favorable MCO coverage, further intensified by the introduction of…
Report
Psoriasis – Landscape & Forecast – Disease Landscape & Forecast (G7)
The psoriasis therapy market has become increasingly lucrative due to the growing use of targeted agents. The newer IL-17 and IL-23 inhibitors (e.g., Eli Lilly’s Taltz, Johnson & Johnson…
Report
Psoriasis – Unmet Need – Unmet Need – Moderate to Severe Psoriasis (US/EU)
Topical therapies are the backbone of psoriasis management; however, they are often inadequate for patients with moderate to severe disease, who typically require systemic treatment. While…
Report
Psoriasis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Adult Psoriasis (US)
The treatment of adult psoriasis represents an increasingly lucrative market for nonconventional systemic therapies, particularly for moderate to severe cases where conventional systemic and…
Report
Psoriasis | Access and Reimbursement | EU | 2019
MARKET OUTLOOK The treatment landscape for psoriasis in the top 5 European markets (France, Germany, Italy, Spain, UK) is extremely dynamic. Humira (AbbVie), Enbrel (Amgen), Stelara (Janssen),…